Poxel | Sustainability Performance
Poxel is a biopharmaceutical company focused on developing treatments for metabolic and neurodegenerative diseases. The company emphasizes innovative research and development to create effective therapies aimed at improving patient outcomes and addressing unmet needs.
2009
France
1,001 - 5,000 employees
Biotechnology
$1M - 10M in revenue
Not profitable
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#3677
Overallⓘ#236
in Franceⓘ#61
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Digital emissionsGovernance
Targets
Controversy level
- Poxel reported significant losses after clinical trial setbacks for its diabetes drug imeglimin in Western markets, raising going-concern risks.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
7-10
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.